Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

HCWB - HCW Biologics Inc. Stock Price, Fair Value and News

$3.41-0.15 (-4.21%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

HCWB Price Action

Last 7 days

-19.6%

Last 30 days

-20%

Last 90 days

-58.6%

Trailing 12 Months

-82%

HCWB RSI Chart

NovDec2025FebMarAprMayJunJulAug0102030405060708090

HCWB Valuation

Market Cap

7.7M

Price/Earnings (Trailing)

-0.67

Price/Sales (Trailing)

0.92

Price/Free Cashflow

-0.6

HCWB Price/Sales (Trailing)

2023202420250100200300400500

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HCWB Fundamentals

HCWB Revenue

Revenue (TTM)

9.4M

Rev. Growth (Yr)

-98.94%

Rev. Growth (Qtr)

-99.8%

202120222023202420254M5M6M7M8M9M

HCWB Earnings

Earnings (TTM)

-11.4M

Earnings Growth (Yr)

87.38%

Earnings Growth (Qtr)

12.25%

20212022202320242025-40M-35M-30M-25M-20M-15M-10M-5M

HCWB Profitability

Operating Margin

92.89%

Return on Equity

21.9K%

Return on Assets

-39.43%

Free Cashflow Yield

-165.91%

HCWB Investor Care

Shares Dilution (1Y)

127.54%

Diluted EPS (TTM)

-17.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20212022202320244M5M6M7M8M9M
Net sales
YearQ1Q2Q3Q4
20250000
20245.8M5.8M4.7M9.4M
20236.7M6.6M6.6M6.6M
20220006.7M
20210000
20200004.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About HCW Biologics Inc.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
 CEO
 WEBSITEhcwbiologics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES44

HCW Biologics Inc. Frequently Asked Questions

What is the ticker symbol for HCW Biologics Inc.? What does HCWB stand for in stocks?

HCWB is the stock ticker symbol of HCW Biologics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of HCW Biologics Inc. (HCWB)?

As of Tue Aug 19 2025, market cap of HCW Biologics Inc. is 7.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HCWB stock?

You can check HCWB's fair value in chart for subscribers.

Is HCW Biologics Inc. a good stock to buy?

The fair value guage provides a quick view whether HCWB is over valued or under valued. Whether HCW Biologics Inc. is cheap or expensive depends on the assumptions which impact HCW Biologics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HCWB.

What is HCW Biologics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Aug 19 2025, HCWB's PE ratio (Price to Earnings) is -0.67 and Price to Sales (PS) ratio is 0.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HCWB PE ratio will change depending on the future growth rate expectations of investors.